Welcome to our dedicated page for THERALASE TECHS news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on THERALASE TECHS stock.
Theralase Technologies Inc. reports company developments as a clinical-stage pharmaceutical developer of energy-activated small molecules for the destruction of cancer, bacteria and viruses. Its updates center on Ruvidar® (TLD-1433), including clinical and regulatory disclosures tied to non-muscle invasive bladder cancer and research into antiviral mechanisms such as HSV-1 inactivation.
Recurring announcements also cover operating and financial results, non-brokered private placements, line-of-credit financing, capital-structure disclosure, governance matters and development collaborations. The company’s news commonly links research progress with funding needs, regulatory pathways, intellectual-property considerations and commercialization risks for its small-molecule drug formulations.
Theralase (TLTFF) reported Q2 2026 interim results and updated Phase II bladder cancer clinical data for its Ruvidar-based Study II.
For the six months ended June 30, 2026, total revenue was $296,927, down 5% from 2025, with gross margin rising to 50% of revenue versus 42% a year earlier. Net loss narrowed 14% to $2,093,926, driven mainly by a 25% reduction in net R&D expenses to $1,101,126. Cash increased to $5,260,832 at June 30, 2026, and a subsequent August 24, 2026 private placement raised $3,555,000 in gross proceeds.
In Study II Cohort 1, 58 of 89 patients (65.2%) achieved complete response at any time, with 40.4% of responders maintaining complete response for 450 days. Kaplan‑Meier analysis estimated cancer‑free probabilities of 48.6%, 34.5% and 25.4% at 1, 2 and 3 years, respectively. Theralase plans NDS/NDA submissions for Ruvidar starting in 4Q 2026, with marketing decisions anticipated in 2027, and is preparing a combinational study with Adstiladrin subject to FDA approval.
Theralase (TLTFF) has commenced Good Laboratory Practice (GLP) toxicology analysis of intravenously administered Rutherrin, its patented Ruvidar–transferrin cancer therapeutic.
The GLP program is designed to determine the optimum intravenous dose to support first-in-human clinical studies for glioblastoma multiforme (GBM), non-small cell lung cancer (NSCLC) and muscle-invasive bladder cancer (MIBC), with pancreatic and colorectal cancers to be investigated as the program advances. Completion of the GLP toxicology analysis is expected in 2026, with results anticipated in early 2027. The company states that, if successful, the data could enable an adaptive clinical development program, broader clinical indications and potential future partnerships or licensing opportunities.
Theralase (TSXV: TLT, OTCQB: TLTFF) reported unaudited results for the six months ended June 30, 2026, alongside updates on its Phase II bladder cancer program and oncology pipeline. Revenue was $296,927, down 5% year over year, with cost of sales of $146,981 and gross margin of $149,946 (50% of revenue versus 42% in 2025). Net loss narrowed 14% to $2,093,926, driven mainly by a 25% reduction in net R&D expenses to $1,101,126. Cash was $5,260,832 at June 30, 2026, and the company subsequently raised $3,555,000 in a brokered private placement.
In Study II for BCG-unresponsive NMIBC CIS, 89 patients were evaluable, with a complete response rate of 65.2% and total response rate of 73.0%. At 450 days, 40.4% of evaluable complete responders maintained CR, and safety was reported in 82/82 patients. Theralase plans rolling NDS/NDA submissions for Ruvidar in 3Q2026 and is preparing a combination cohort with Ferring’s Adstiladrin, while advancing Rutherrin GLP toxicology toward adaptive trials targeted for 2027.
Theralase Technologies (TSXV: TLT, OTCQB: TLTFF) has granted an aggregate of 7,000,000 stock options under its stock option plan to eligible participants. The options have an exercise price of C$0.265 per common share, vest over three years, and expire five years from the grant date.
The grant remains subject to acceptance by the TSX Venture Exchange. Theralase describes itself as a clinical stage pharmaceutical company focused on energy-activated small molecules targeting cancer, bacteria and viruses.
Theralase (OTCQB:TLTFF) received a receipt for a final base shelf prospectus dated June 29, 2026, filed across Canada. The prospectus enables offerings of up to C$100 million in various securities over 25 months, though the company currently has no intention to issue securities.
Theralase (TSXV: TLT, OTCQB: TLTFF) received TSX Venture Exchange approval to list up to 20,399,050 common share purchase warrants under symbol TLT.WT, expected to start trading June 9, 2026.
The warrants and 19,166,667 units were issued in a brokered private placement raising C$4.6 million.
Theralase (OTCQB:TLTFF) reported Q1 2026 revenue of $132,634, up 45% year-over-year, with gross margin improving to 49% of revenue. Net loss narrowed to $1,031,785 as research and development spending declined while its Phase II NMIBC bladder cancer Study II nears completion.
Interim data show a 65.2% complete response rate (58/89) and 40.4% 12‑month durability (21/52), with the safety endpoint met in 82/82 patients. Theralase plans rolling NDA submissions to Health Canada and FDA in 3Q 2026, targeting decisions in 1H 2027.
Theralase (OTCQB: TLTFF) released audited 2025 financials and interim Study II clinical results for Ruvidar (TLD-1433) in BCG-unresponsive NMIBC CIS. Revenue fell 21% to C$816,468; net loss was C$4,120,817 in 2025. Interim efficacy: 65.2% complete response (58/89); 40.4% maintained CR at 450 days (21/52).
The company announced a collaborative clinical development agreement with Ferring and intends to file an NDS/NDA in 3Q2026 with decisions expected in 1H2027.
Theralase (OTCQB: TLTFF) reported a complete response in a preclinical orthotopic muscle-invasive bladder cancer (MIBC) animal study: 100% of animals treated with X‑Ray‑activated Rutherrin remained cancer‑free at study end, while radiation‑only and untreated groups showed progressive mortality.
The Kaplan–Meier analysis demonstrates durable survival benefit. Pending GLP toxicology, the company plans a Phase 0/I/II adaptive clinical study in MIBC in 2026, subject to regulatory approval.
Theralase (OTCQB: TLTFF) closed a combined financing totaling CAN$2.66 million on April 10, 2026, including a CAN$1.665M non-brokered unit offering and a CAN$1.0M revolving line of credit.
Units issued: 6,404,700 at CAN$0.26 (one share + one warrant, 5-year CAN$0.36 exercise). Insider subscriptions totaled 937,400 units. Proceeds will fund a Phase II NMIBC CIS study, GLP toxicology for Rutherrin, and working capital.